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Abstract	
	
Protein	 kinases	 are	 central	 players	 in	 the	 regulation	of	 cell	 cycle	 and	 signalling	 pathways.	
Their	 catalytic	activities	are	 strictly	 regulated	 through	post-translational	modifications	and	
protein-protein	 interactions	 that	 control	 switching	 between	 inactive	 and	 active	 states.	
These	 states	 have	 been	 studied	 extensively	 using	 protein	 crystallography,	 although	 the	
dynamic	nature	of	protein	kinases	makes	it	difficult	to	capture	all	relevant	states.	Here	we	
describe	two	recent	structures	of	Aurora-A	kinase	that	trap	its	active	and	inactive	states.	In	
both	cases,	Aurora-A	is	trapped	through	interaction	with	a	synthetic	protein,	either	a	single	
domain	 antibody	 that	 inhibits	 the	 kinase	 or	 a	 hydrocarbon-stapled	 peptide	 that	 activates	
the	 kinase.	 These	 structures	 show	 how	 the	 distinct	 synthetic	 proteins	 target	 the	 same	
allosteric	 pocket	 with	 opposing	 effects	 on	 activity.	 These	 studies	 pave	 the	 way	 for	 the	
development	of	tools	to	probe	these	allosteric	mechanisms	in	cells.	
	
Introduction	
	
Many	 of	 the	 key	 signalling	 and	 regulatory	 events	 inside	 cells	 involve	 protein	
phosphorylation,	a	reversible	and	ubiquitous	post-translational	modification	carried	out	by	
protein	kinases.		The	human	genome	encodes	more	than	500	protein	kinase	domains,	most	
of	 which	 are	 found	 in	 the	 context	 of	 a	 multidomain	 polypeptide	 chain,	 and	 many	 are	
components	 of	multi-protein	 complexes	 [1].	 The	 catalytic	 activities	 of	 protein	 kinases	 are	
regulated	 through	 interactions	 with	 these	 other	 domains	 and	 also	 by	 post-translational	
modifications	 [2].	Protein-protein	 interactions	also	 serve	 to	 localise	 signalling	pathways	 to	
specific	 sub-cellular	 localisations	 to	defined	multi-protein	 complexes	 that	 assemble	 at	 the	
sites	of	kinase	activity.		
	
Protein	kinases	have	conserved	sequence	and	structural	features	that	are	organised	into	a	
similar	 conformational	arrangement	when	 the	kinase	 is	 in	an	active	 state	 (Figure	1a,b).	 In	
contrast,	these	features	are	displaced	in	many	different	ways	when	a	kinase	is	inactive.	The	
catalytic	domain	of	a	protein	kinase	comprises	two	sub-domains	or	lobes,	between	which	a	
molecule	of	ATP	binds.	The	N-lobe	is	formed	from	a	b-sheet	and	at	least	one	a-helix,	usually	
called	the	C-helix	based	on	the	canonical	PKA	structure	[3].	The	C-lobe	is	mostly	helical	and	
has	 an	 extended	 loop	 structure	 called	 the	 activation	 loop,	 activation	 segment	 or	 T-loop,	
which	is	the	site	of	regulatory	phosphorylation	and	forms	part	of	the	binding	site	for	protein	
substrates.	The	 structural	basis	of	protein	kinase	activation	has	been	 the	 subject	of	many	
research	 articles,	 and	 has	 been	 extensively	 reviewed	 elsewhere	 [2,	 4-7].	 Therefore,	 for	
reasons	of	brevity	we	will	focus	on	a	subset	of	concepts	relevant	to	the	allosteric	regulation	
of	Aurora-A.	Three	features	in	particular	are	hallmarks	of	kinase	active	or	inactive	states:	a	
Lys-Glu	salt-bridge,	the	regulatory	(R-)	spine	and	the	activation	loop	(Figure	1a,b).	The	Lys-
Glu	salt	bridge	brings	together	the	b-sheet	and	C-helix	and	helps	to	position	the	phosphates	
of	ATP	 for	 catalysis	 [2,	 5].	 The	R-spine	 is	 a	 set	 of	 four	hydrophobic	 residues	 that	 connect	
these	same	two	major	structural	elements	of	the	N-lobe	with	the	C-lobe.	The	side	chains	of	
the	 R-spine	 residues	 form	 a	 connected,	 roughly	 linear	 pattern	 in	 active	 kinases,	 but	 are	
displaced	from	this	arrangement	in	inactive	kinases	[4,	6].	
	
Structural	 and	 biochemical	 studies	 have	 defined	 the	 molecular	 basis	 of	 protein-protein	
interactions	 (PPIs)	 involving	 kinases.	 As	 well	 as	 kinase-substrate	 interactions,	 regulatory	
interactions	 of	 kinases	may	 involve	 symmetric	 or	 asymmetric	 dimerization	or	 interactions	
with	other	binding	partners.	Studies	of	protein-protein	interactions	typically	rely	on	genetic	
approaches.	 Small	 molecule	 inhibitors	 offer	 greater	 flexibility	 in	 terms	 of	 application	 to	
different	 cell	 types	 and	 the	 ability	 to	 deliver	 a	 known	 dose	 at	 a	 specified	 time	 point.	
However,	 the	 development	 of	 small	 molecule	 PPI	 inhibitors	 has	 considerable	 time	 and	
monetary	 costs.	 Moreover,	 the	 expertise	 required	 to	 carry	 out	 chemical	 synthesis	 is	 not	
usually	available	 in	a	 typical	molecular,	 cell	or	 structural	biology	 laboratory.	We	 therefore	
began	to	exploit	the	potential	of	peptide	and	protein-based	reagents	to	target	the	protein-
protein	 interactions	 of	 a	 model	 Ser/Thr	 protein	 kinase,	 Aurora-A,	 a	 key	 regulator	 of	 cell	
division	[8].		
	
	
Phosphorylation	and	interactions	coordinate	to	activate	Aurora-A	
	
Aurora-A	 is	 related	 to	 the	 AGC	 family	 of	 Ser/Thr	 kinases,	 which	 are	 activated	 by	
phosphorylation	of	a	site	in	their	activation	loop	and,	in	many	cases,	one	or	more	sites	in	a	
region	C-terminal	to	the	catalytic	domain	[9].	A	hallmark	of	AGC	kinases	is	their	activation	by	
a	hydrophobic	(HF)	motif	within	a	C-terminal	extension	to	the	kinase	domain	that	fits	into	a	
hydrophobic	 surface	 on	 the	 N-lobe	 between	 the	 b-sheet	 and	 the	 C-helix	 called	 the	 PIF	
pocket	(Figure	1c)	[9,	10].	In	addition,	some	AGC	kinases	have	a	helical	N-terminal	extension	
from	which	Trp	and	Phe	(F/W)	side	chains	protrude	into	a	groove	between	the	C-helix	and	
activation	loop	(Figure	1c)	[11].		PDK1	is	an	AGC	kinase	that	lacks	a	HF	motif	and,	instead,	its	
PIF	pocket	 is	used	to	recruit	other	AGC	kinases,	such	as	PKB/AKT	and	RSK,	which	are	then	
phosphorylated	and	activated	[9].	This	property	has	been	exploited	in	the	development	of	
small	molecules	 that	bind	 to	 the	PIF	pocket	 and	block	 interactions	 and,	 interestingly,	 this	
same	pocket	 can	be	used	 to	 activate	or	 inhibit	 PDK1	 [12-14].	Aurora-A	has	 a	 similar	 core	
catalytic	 domain	 to	 AGC	 kinases,	 but	 lacks	 the	 N-	 and	 C-terminal	 extensions	 (Figure	 1d).	
Instead,	 the	 HF	 motif	 and	 F/W	 side	 chains	 are	 provided	 by	 a	 binding	 partner,	 the	
microtubule-associated	 protein	 TPX2	 (Figure	 1e,f)	 [15].	 HF	motifs	 and	 the	 region	 of	 TPX2	
that	interact	with	the	hydrophobic	pocket	are	short	extended	peptides.	However,	the	same	
surface	 area	 of	 the	 catalytic	 domain	 of	 many	 other	 kinases	 is	 involved	 in	 regulatory	
interactions	 with	 an	a-helix	 on	 the	 surface	 of	 a	 folded	 partner	 protein,	 for	 example	 the	
binding	 of	 cyclins	 to	 CDKs,	 and	 the	 asymmetric	 dimerization	 of	 EGFR.	 The	 hydrophobic	
pocket	 of	 kinases	 is	 therefore	 a	 versatile	 binding	 site,	 able	 to	 accommodate	 an	 extended	
peptide,	an	a-helix	or	an	organic	compound	of	low	molecular	weight.	
	
Aurora-A	 has	 an	 intrinsically	 low	 level	 of	 catalytic	 activity	 that	 is	 boosted	 through	
autophosphorylation	on	Thr288,	one	of	a	pair	of	adjacent	threonine	residues	in	a	region	of	
the	kinase	called	the	activation	loop	[16].	The	mechanism	of	autophosphorylation	remains	
undecided,	with	biochemical	evidence	in	support	of	both	intramolecular	and	intermolecular	
mechanisms	 [17,	 18].	 Aurora-A	 activity	 is	 also	 promoted	 through	 interaction	with	 protein	
binding	 partners,	 such	 as	 the	 microtubule-associated	 proteins	 TPX2	 and	 TACC3,	 the	
centrosomal	protein	Cep192,	the	ciliary	protein	Pifo	and	the	transcription	factor	N-Myc	[15,	
19-23].	These	regulatory	partners	stimulate	autophosphorylation	and,	at	least	in	the	case	of	
TPX2	 in	 vitro,	 these	 two	 activation	 steps	 can	 combine	 synergistically	 to	 produce	 a	
hyperactive	 form	of	 the	kinase	 (Figure	2a)	 [24].	Crystal	 structures	of	Aurora-A	 in	different	
states	 of	 activity	 suggest	 a	 pathway	 for	 step-wise	 kinase	 activation	 (Figure	 2b).	 In	 its	
unphosphorylated	form,	Aurora-A	has	been	captured	 in	an	 inactive	conformation	 in	which	
the	R-spine	and	C-helix	are	distorted,	disrupting	a	salt	bridge	between	Glu181	and	Lys162,	
and	 the	 activation	 loop	 is	 disordered	 or	 rearranged	 [18,	 25].	 Interestingly,	 the	 R-spine	 of	
Aurora-A	is	unusual	in	that	the	C-helix	component	is	not	hydrophobic,	but	is	polar	(Gln185).	
The	side	chain	of	this	residue	forms	a	H-bond	with	the	main	chain	in	the	b-sheet,	is	critical	
for	 the	 activity	of	 the	 kinase,	 and	may	 contribute	 to	 the	 selectivity	of	Aurora-A	 inhibitors	
[26,	27].			Phosphorylation	of	Aurora-A	on	Thr288	or	Thr287,	reinforces	the	proper	position	
of	 the	 C-helix	 and	 activation	 loop	 through	 interactions	 with	 a	 set	 of	 basic	 residues,	
interactions	that	can	be	mimicked	in	crystal	structures	by	inorganic	phosphate	[15,	28,	29].		
Alternatively,	 TPX2	 binding	 on	 its	 own	 is	 sufficient	 to	 stabilize	 an	 active	 conformation	 of	
Aurora-A,	which	is	then	able	to	autophosphorylate	[18].	This	 is	because	TPX2	binds	to	and	
stabilises	the	C-helix	through	the	interaction	of	hydrophobic	side	chains,	starting	with	a	pair	
of	tyrosine	residues	that	bind	into	a	so-called	Y	pocket,	which	is	at	the	equivalent	position	in	
the	 structure	 to	 the	 PIF	 pocket	 of	 AGC	 kinases.	 However,	 TPX2	 dramatically	 enhances	
Aurora-A	activity	even	in	the	absence	of	phosphorylation,	i.e.	when	Thr288	is	mutated	to	a	
non-phosphorylatable	 residue	 [18,	 24].	 This	 is	 of	 physiological	 relevance	 because,	 at	 the	
location	of	the	Aurora-A/TPX2	complex	along	spindle	microtubules,	Aurora-A	is	maintained	
in	 a	 dephosphorylated	 state	 by	 PP6	 phosphatase	 [30].	 TPX2	 stimulates	 the	 activity	 of	
Aurora-A	that	is	phosphorylated	on	Thr288	and	protects	this	site	from	dephosphorylation	by	
other	phosphatases	such	as	PP1.	This	is	explained	by	the	observation	that	the	conformation	
of	the	activation	loop	matches	that	found	in	related	kinase-substrate	complexes	only	in	the	
presence	of	TPX2	[15].		
	
Small	 molecule	 inhibitors	 of	 Aurora-A	 have	 been	 developed	 and	 are	 under	 clinical	
evaluation	as	potential	 cancer	 therapeutics	 [31].	Because	 they	bind	 to	 the	 conserved	ATP	
site	of	the	kinase,	they	have	off-target	activity	that	may	contribute	to	toxicity.	We	reasoned	
that	 targeting	 less-conserved	 allosteric	 sites	 may	 result	 in	 compounds	 with	 superior	
selectivity,	and	would	have	the	potential	for	diverse	mechanisms	of	action	such	as	inhibition	
or	activation,	or	disruption	of	protein-protein	 interactions.	As	a	starting	point,	we	recently	
explored	proteomimetic	approaches	 to	 trap	Aurora-A	 in	active	and	 inactive	 states	using	a	
single	domain	antibody	(sdAb)	or	hydrocarbon-stapled	peptide.	
	
An	allosteric,	antibody-based	inhibitor	of	Aurora-A	
Single	 domain	 scaffolds	 such	 as	 nanobody,	monobody	 and	 adhiron	 can	 be	 used	 to	 block	
protein-protein	 interactions	 and	 to	 trap	 specific	 conformational	 states	 [32].	 Because	 they	
are	 genetically	 encoded,	 they	 can	 be	 expressed	 in	 cell	 models	 of	 disease	 to	 investigate	
signalling	 pathways,	 synergy	 with	 other	 inhibitors	 and	 resistance	 mechanisms.	 These	
reagents	 are	 based	 on	 stable	 protein	 scaffolds	 from	which	 loops	 are	 displayed	 that	 form	
protein-protein	 interactions.	 Libraries	 can	 be	 generated	 in	 which	 the	 loop	 length	 and	
sequence	are	varied.	For	example,	varying	seven	amino	acids	gives	 rise	 to	over	 ten	billion	
distinct	proteins	and	yet	screening	of	these	libraries	is	both	feasible	and	inexpensive	using	
biotechnological	methods	such	as	phage	display.	
	
There	 are	 a	 few	 reported	 studies	 in	 which	 sdAbs	 have	 been	 used	 to	 activate	 or	 inhibit	
kinases	 through	 interactions	 with	 regulatory	 domains	 [33,	 34].	 We	 recently	 described	 a	
sdAb,	 vNAR-D01,	 based	 on	 a	 shark	 sdAb,	 that	 targets	 the	 catalytic	 domain	 of	 Aurora-A	
kinase	 and	 competes	 with	 the	 TPX2	 interaction	 [35].	 	 A	 crystal	 structure	 of	 the	 Aurora-
A/vNAR-D01	 complex	 shows	 that	 the	 sdAb	 overlaps	with	 the	 TPX2	 binding	 site	 at	 the	 C-
helix,	 inserting	 the	 indole	 ring	 of	 a	 tryptophan	 side	 chain	 into	 the	 Y	 pocket	 (Figure	 3a-c).	
However,	 in	contrast	with	 the	binding	of	TPX2,	which	stabilizes	an	active	conformation	of	
the	kinase,	binding	of	vNAR-D01	stabilizes	an	inactive	conformation	that	closely	resembles	
that	observed	with	unphosphorylated	Aurora-A.	Two	key	interactions	between	the	b-sheet	
and	 the	 C-helix,	 the	 salt-bridge	 formed	 by	 Glu181	 and	 Lys162,	 and	 the	 H-bond	 between	
Gln185	 of	 the	 R-spine	 and	 Leu194,	 are	 both	 disrupted	 in	 the	 inactive	 conformation.	
Therefore,	we	believe	that	sdAbs	will	be	useful	to	trap	kinases	in	an	inactive	conformation	
to	facilitate	structural	studies	on	inactive	forms.		
	
The	 vNAR	 single	 domain	 antibody	 scaffold	 has	 three	 variable	 regions	 that	 provide	
opportunities	to	optimize	potency	and	tailor	selectivity	by	contacting	multiple	points	on	the	
target’s	surface.	For	example,	in	the	complex	with	Aurora-A,	the	HV2/CDR1	region	of	vNAR-
D01	contacts	the	activation	 loop	of	Aurora-A,	an	 interaction	that	could	be	manipulated	to	
further	enhance	 inhibition	through	stabilization	of	an	 inactive	conformation	 in	this	flexible	
region	of	the	kinase.	The	region	of	Aurora-A	to	which	vNAR-D01	binds	is	conserved	in	most	
other	 kinases	 at	 the	 level	 of	 tertiary	 structure,	 if	 not	 sequence.	 It	 is	 therefore	 likely	 that	
allosteric	 inhibitors	 targeting	 other	 protein	 kinases	 based	 on	 this	 scaffold	 could	 be	
identified.	It	is	also	conceivable	that	the	scaffold	could	be	modified	to	activate	Aurora-A	or	
other	kinases.	Single	domain	antibodies	that	control	kinase	activity	could	be	useful	for	the	
localized	 regulation	 of	 kinase	 activity	 within	 cells,	 providing	 unique	 tools	 to	 manipulate	
signalling	pathways.		
	
An	allosteric,	proteomimetic	activator	of	Aurora-A	
	Constrained	 peptides	 have	 been	 generated	 that	 target	 a	 range	 of	 different	 biologically	
relevant	PPIs	[36].	The	first	example	of	this	applied	to	a	kinase	was	to	block	the	dimerization	
and	 subsequent	 activation	 of	 EGFR	 using	 triazolyl-bridged	 peptides	 that	 mimic	 one	
component	of	the	dimerization	interface	[37].	Another	way	of	forming	constrained	peptides	
is	 through	 hydrocarbon-stapling	 of	 an	 α-helix,	 which	 is	 achieved	 by	 replacing	 the	 native	
amino	acids	at	two	positions	in	the	sequence	spaced	3,	4	or	7	residues	apart	with	unnatural	
amino	acids	that	form	a	cross-link	(or	chemical	staple)	[38].	We	recently	applied	this	method	
to	 TPX2,	 which	 has	 an	 α-helix	 that	 forms	 upon	 interaction	 with	 the	 activation	 loop	 of	
Aurora-A	 [39].	 A	 synthetic	 variant	 of	 this	 region	 of	 TPX2,	 residues	 30-43,	 in	 which	 the	
residues	at	positions	37	and	41	were	replaced	with	α-methyl,	α-alkenyl	amino	acid	(S5)	was	
prepared	 and	 macrocyclised	 using	 ring-closing	 olefin	 metathesis.	 Circular	 dichroism	
spectroscopy	confirmed	that	the	stapled	peptide	was	helical,	unlike	the	equivalent	peptide	
based	on	a	native	TPX2	sequence.	The	stapled	helix	segment	was	incorporated	into	a	longer	
peptide	comprising	 residues	1-43	of	TPX2	 (sTPX2)	 that	had	enhanced	binding	 to	Aurora-A	
compared	to	the	native	TPX2	sequence	as	measured	by	isothermal	titration	calorimetry.		
	
The	synthetic	protein	sTPX2	activated	Aurora-A	autophosphorylation	to	the	same	extent	as	
recombinant	TPX2	1-43	and	therefore	retained	the	principal	function	of	this	fragment	of	the	
native	protein.	The	crystal	 structure	of	 the	complex	 revealed	a	similar	yet	more	extensive	
interface	 between	 the	 stapled	 TPX2	 (sTPX2)	 and	 Aurora-A	 (Figure	 3d-f).	 As	 expected,	 the	
staple	itself	does	not	interact	with	the	Aurora-A	surface.		The	stapled	helix	has	an	extra	half	
turn,	 resulting	 in	 the	 formation	 of	 additional	 salt	 bridges	 between	 Glu36	 and	 Lys38	 and	
Aurora-A,	which	might	contribute	to	enhanced	binding.		
	Future	prospects	
	
The	 inhibition	of	Aurora-A	by	vNAR-D01	provides	compelling	evidence	that	 the	kinase	can	
be	 targeted	 through	 this	 allosteric	 mechanism.	 Moreover,	 the	 structure	 of	 the	 complex	
provides	a	good	starting	point	for	computational	design	of	small	molecule	ligands	that	bind	
to	 this	 pocket.	 Conformational	 stabilization	 has	 the	 advantage	 of	 generating	 higher	
resolution	data	on	the	inactive	state	of	Aurora-A,	 improving	from	2.79Å	(PDB	4C3P)	 in	the	
absence	of	sdAb	to	1.67	Å/	1.79	Å	(PDB	5L8L/5L8K)	in	the	presence	of	vNAR-D01.			
	
The	first	small	molecule	inhibitors	that	target	the	Y	pocket	of	Aurora-A	have	recently	been	
reported	 [40].	 The	 most	 advanced	 compound	 that	 has	 been	 disclosed,	 AurkinA,	 binds	
Aurora-A	with	a	Kd	of	3.77	µM	and,	consistent	with	its	binding	mode,	competes	with	TPX2	
but	not	ATP.	Interestingly,	the	crystal	structure	of	the	Aurora-A/AurkinA	complex	appears	to	
be	very	similar	to	that	of	Aurora-A	in	a	pre-active	conformation	with	the	Lys162-Glu181	salt-
bridge,	 the	Gln185-Leu194	H-bond	and	all	 secondary	structure	elements	 in	 their	expected	
positions	(Figure	3g-i).	There	are	subtle	shifts	in	the	positions	of	the	side	chains	around	the	
inhibitor	binding	site,	but	the	kinase	is	not	locked	into	an	inactive	conformation,	unlike	the	
vNAR-D01	 structure	 (Figure	 3h).	 It	 will	 be	 very	 interesting	 to	 see	 how	 these	 compounds	
develop,	and	whether	optimized	compounds	stabilise	an	inactive	conformation	of	Aurora-A	
similar	to	that	recognised	by	vNAR-D01.		
	
The	mechanism	of	Aurora-A	inhibition	by	vNAR-D01	is	potentially	relevant	to	other	kinases	
because	activation	mechanisms	often	 involve	movements	of	 the	C-helix	 [2].	 Furthermore,	
cancer	mutations	 in	 this	 region	of	 the	 kinase	 structure	promote	activation	 [41].	Allosteric	
kinase	 inhibitors	 that	 exploit	 this	 property	 include	 PDK1	 inhibitors	 that	 bind	 to	 the	 PIF	
pocket,	equivalent	 to	 the	Y	pocket	of	Aurora-A	 [14].	Protein-protein	 interactions	 involving	
kinases	represent	a	rich,	virtually	untapped	source	of	targets	for	therapeutic	intervention	in	
disease.	 We	 believe	 that	 sdAbs	 and	 stapled	 peptides	 could	 be	 very	 useful	 tools	 for	 the	
investigation	of	protein-protein	interactions	during	the	target	validation	phase	of	a	project.		
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Figure	Legends	
Figure	1.	Schematic	model	of	the	Aurora-A	activation	pathway	
(a)	 Crystal	 structure	 of	 protein	 kinase	A	 (PKA,	 PDB	 1JBP)	 shows	 the	N-	 (NTE,	 teal)	 and	 C-	
(CTE,	 pink)	 terminal	 extensions	 to	 the	 catalytic	 domain,	 the	 activation	 loop	 (green)	 that	
harbours	an	activating	phosphorylated	threonine	(green	spheres),	ADP	(white	spheres),	the	
R-spine	(orange	surface),	the	C-helix	(aC)	and	the	Lys-Glu	salt-bridge	(blue	and	red	spheres	
and	 lines,	 respectively).	 (b)	 Schematic	 illustration	 of	 the	 active	 conformation	 of	 PKA.	
Features	coloured	as	in	(a).	(c)	Magnified	view	of	the	hydrophobic	grooves	on	the	surface	of	
the	 catalytic	domain	 into	which	hydrophobic	 residues	 from	 the	NTE	 and	CTE	are	 inserted	
(teal	and	pink	spheres,	 respectively).	 (d)	Crystal	 structure	of	Aurora-A/TPX2	complex	 (PDB	
1OL5)	shows	how	two	stretches	of	TPX2	sequence	(teal	and	pink)	mimic	the	NTE	and	CTE	of	
PKA.	Residues	coloured	as	 in	 (a).	 (e)	Schematic	 illustration	of	 the	Aurora-A/TPX2	complex.	
Features	coloured	as	in	(d).	(f)	Magnified	view	of	the	hydrophobic	grooves	on	the	surface	of	
Aurora-A	into	which	hydrophobic	residues	from	TPX2	are	inserted.	Features	coloured	as	in	
(d).	
	
Figure	2.	Multi-step	activation	of	Aurora-A	
(a)	 The	 step-wise	 increase	 in	 Aurora-A	 activity	 upon	 TPX2	 binding	 and	 phosphorylation	 is	
shown	 from	 bottom	 to	 top	 using	 published	 values	 [24].	 (b)	 The	 step-wise	 activation	 of	
Aurora-A	is	shown	schematically	from	left	to	right,	with	the	relative	activity	indicated	by	the	
colour	 surrounding	 the	 ATP,	 which	 matches	 the	 corresponding	 bar	 in	 the	 chart	 in	 (a).	
Unphosphorylated	Aurora-A	has	been	captured	in	both	partially	(or	pre-)	active	and	inactive	
conformations,	as	 indicated	by	the	presence	or	absence	of	a	Lys-Glu	salt-bridge	(indicated	
by	 joined	 or	 disconnected	 blue-red	 lines),	 as	 observed	 in	 the	 crystal	 structures	with	 PDB	
1MQ4/1OL6	and	4C3R,	respectively.	The	activation	loop	is	usually	disordered	(as	shown	by	
the	thick,	dashed	grey	line)	or	trapped	in	a	flipped	conformation	in	the	presence	of	specific	
ATP-competitive	 ligands,	as	found	in	PDB	1MUO	and	2WTV.	Crystal	structures	of	Aurora-A	
phosphorylated	on	Thr288	(green	star;	e.g.	PDB	1OL7	and	4CEG)	or	bound	to	TPX2	(pink	and	
teal;	 PDB	 4C3P)	 show	 a	 pre-active	 conformation	with	 a	 clear	 Lys-Glu	 salt-bridge,	 and	 the	
activation	loop	is	more	ordered	but	is	not	fixed	in	a	conformation	compatible	with	substrate	
binding.	 The	 combination	 of	 TPX2	 and	 phosphorylation	 on	 Thr288	 generates	 an	 active	
conformation	with	all	structural	elements	 in	place	for	substrate	binding	and	catalysis	(PDB	
1OL5).	
	
	
Figure	3.	Crystal	structures	of	Aurora-A	in	complex	with	synthetic	regulators	
(a)	 Phosphorylated	Aurora-A	 (grey)	 in	 complex	with	 vNAR-D01	 (yellow),	 a	 synthetic	 shark	
single	domain	antibody,	is	trapped	in	an	inactive	conformation	as	shown	by	the	broken	Lys-
Glu	salt-bridge	(blue	and	red	spheres,	respectively).	PDB	5L8L.	(b)	Schematic	 illustration	of	
the	Aurora-A/vNAR-D01	complex.	(c)	Magnified	view	of	the	Y	pocket	in	the	Aurora-A/vNAR-
D01	complex.	(d)	Phosphorylated	Aurora-A	(grey)	in	complex	with	sTPX2	(green),	a	synthetic	
hydrocarbon-stapled	peptide	of	the	human	TPX2	protein	residues	1-43,	is	found	in	an	active	
conformation	with	an	intact	Lys-Glu	salt-bridge.	PDB	5LXM.	(e)	Schematic	illustration	of	the	
Aurora-A/sTPX2	complex.	(f)	Magnified	view	of	the	Y	pocket	in	the	Aurora-A/sTPX2	complex.	
(g)	 Aurora-A	 (grey)	 in	 complex	 with	 AurkinA	 (pink),	 a	 small	 molecule	 allosteric	 inhibitor,	
adopts	 an	 active	 conformation	 with	 an	 intact	 Lys-Glu	 salt-bridge	 (teal	 and	 pink	 spheres,	
respectively).	PDB	5DT4.	(h)	Superposition	of	Aurora-A	structures	 in	complex	with	AurkinA	
(coloured	as	in	(g))	and	vNAR-D01	(coloured	as	in	(a)).	Note	the	binding	of	the	two	inhibitors	
to	 the	Y	pocket.	 (i)	Magnified	view	of	 the	Y	pocket.	AurkinA	 is	 represented	by	pink	sticks.	
Kinase	features	are	coloured	as	in	Figure	1.	
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